TNFRSF8 and anaplastic large cell lymphoma: In 2017, Ramos et al. published a report from a phase I dose-escalation clinical trial (NCT01316146) with 7 R/R HL or 2 ALCL patients who received CD30-redirected second-generation CAR-Ts [79].